Skip to main content
Premium Trial:

Request an Annual Quote

Biogen Idec Provides $5.3M for Collaboration with Whitehead Scientists

NEW YORK (GenomeWeb News) – Scientists at the Whitehead Institute will use $5.3 million over the next three years from Biogen Idec to pursue research projects involving genomics, genetics, immunology, neurology, developmental biology, and other approaches.

Under a new research collaboration agreement, the funding from the Weston, Mass.-based drug developer will support early stage research projects addressing a wide array of disease areas, the Whitehead Institute said yesterday.

These Whitehead investigators will pair up with scientists at Biogen Idec, and together they will develop integrated and collaborative research projects. A joint committee of scientists from Whitehead and Biogen Idec will determine which projects will receive funding.

"This collaboration demonstrates our joint commitment to finding ways to better understand the underlying biology of complex diseases, focusing on innovative initiatives where together we can drive new insights through cutting-edge research," Biogen Idec's CSO Spyros Artavanis-Tsakanos said in a statement.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more